Endogenous Orphanin FQ/Nociceptin Is Involved in the Development of Morphine Tolerance
Authors:
- Sigrun PohlSPSigrun Pohl
- Joanne ZengJZJoanne Zeng
- Olivier CivelliOCOlivier Civelli
- Rainer K. ReinscheidRRRainer K. Reinscheid
- 1 July 2006
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 318 (1) , 262-267
Abstract
The neuropeptide orphanin FQ/nociceptin (OFQ/N) has been shown to counteract several effects of endogenous and exogenous opioids, and it has been proposed as an opioid-modulating agent involved in the development of morphine tolerance and dependence. However, conflicting results have been obtained from animal models using different protocols to induce morphine tolerance. Here, we report that both genetic and pharmacological blockade of OFQ/N signaling can effectively prevent development of morphine tolerance. OFQ/N knockout mice injected daily with low doses of morphine (10 mg/kg) fail to develop tolerance even after 3 weeks of treatment, whereas their wild-type litter mates show profound tolerance starting after 10 days. Likewise, coadministration of morphine together with the synthetic N/OFQ peptide antagonist, J-113397 (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one), is able to block tolerance development in normal mice. These data indicate that release of endogenous OFQ/N after morphine administration might produce a gradual decline of analgesic potency, i.e., tolerance. Interestingly, tolerant and nontolerant groups of mice receiving repeated daily low morphine doses did not differ in their withdrawal behavior after naloxone injection. In contrast, mice receiving escalating doses of morphine developed analgesic tolerance independent of their OFQ/N genotype, whereas withdrawal symptoms were attenuated in OFQ/N-deficient animals. These results indicate that the endogenous OFQ/N system is differentially involved in morphine tolerance development and establishment of opiate dependence, depending on the specific morphine dosage regimen. Furthermore, it suggests that OFQ/N antagonists could provide a novel therapeutic strategy to attenuate morphine tolerance development.Keywords
This publication has 39 references indexed in Scilit:
- The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non‐NOP‐receptor‐mediated mechanismBritish Journal of Pharmacology, 2004
- Genetic variation in morphine analgesic tolerancePharmacology Biochemistry and Behavior, 2002
- Functional Dissociation of μ Opioid Receptor Signaling and EndocytosisNeuron, 1999
- Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the ratJournal of Comparative Neurology, 1999
- Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor geneNature, 1996
- Structure-Activity Relationship Studies on the Novel Neuropeptide Orphanin FQJournal of Biological Chemistry, 1996
- Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled ReceptorScience, 1995
- Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptorNature, 1995
- A review of the role of anti‐opioid peptides in morphine tolerance and dependenceSynapse, 1992
- Inhibition of Morphine Tolerance and Dependence by the NMDA Receptor Antagonist MK-801Science, 1991